Gilead Sciences’ Kite Pharma has expanded its second CAR-T cell therapy, Tecartus, into a leukemia market that overlaps a Novartis territory for Kymirah. The FDA …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
